Twenty-nine human aqueous humor samples from patients with eye diseases such as cataract and glaucoma with and without pseudoexfoliation syndrome were characterized by LC-high resolution MS analysis. In total, 269 protein groups were identified with 1% false discovery rate including 32 groups that were not reported previously for this biological fluid. Since the samples were analyzed individually, but not pooled, 36 proteins were identified in all samples, comprising the constitutive proteome of the fluid. The most dominant molecular function of aqueous humor proteins as determined by GO analysis is endopeptidase inhibitor activity. Label-free protein quantification showed no significant difference between glaucoma and cataract aqueous humor proteomes. At the same time, we found decrease in the level of apolipoprotein D as a marker of the pseudoexfoliation syndrome. The data are available from ProteomeXchange repository (PXD002623).

Extended analysis of clinical, functional and morphological changes in the retina at the onset of DR in type 2 diabetes patients with concomitant "dry" AMD enables timely diagnosis, prognosis, prevention, and early treatment. Conservative treatment with antioxidant and angioprotective agents has been proved effective in type 2 diabetes patients with preclinical (DRO) and early (DR1) diabetic retinopathy and those with DR and "dry" AMD (AREDS 1-3) in terms of functional and morphological parameters of the retina. From all the regimens, a combined antioxidant and double-dose angioprotective (240 mg) therapy appeared to be the most effective and can be considered not only a preventive, but also a therapeutic measure in type 2 diabetes patients with initial stages of DR (DRO, DR1) or those with DR and DM or combined DR and AMD (AREDS 1-3).

Purpose: to assess the changes in visual functions in patients with age related macular degeneration (AMD) and medium to high degree myopia treated with a peptide bioregulator and a multivitamin complex. Material and methods. 60 patients (120 eyes) aged 44 to 79 with age-related changes in the retina treated with peptide bioregulator and/or multivitamin complex were tested for changes of visual functions. The patients, examined before and after treatment with both, were divided into 2 groups depending on treatment type (peptide plus multivitamin vs. multivitamin alone), which were further subdivided into two subgroups depending on the axial length of the eyeball (less than 26.5 mm vs. 26.5 mm or more). Results. A positive response to the therapy (increased visual acuity and improved perimetic parameters) was revealed in patients of both groups with AL < 26.5 mm), which may be accounted for by an initially better state of the retina. The patients of the subgroup with AL  26.5 mm) showed a significant improvement of uncorrected visual acuity, but best corrected visual acuity remained practically the same. Conclusions. The proposed treatment with a polypeptide bioregulator in combination with a multivitamin complex can be used in AMD and myopic patients with retinal pathology.

No abstract

Received: 15.01.201615.01. Accepted: 24.02.2016 G To date, cataract surgery development aims at minimizing surgical trauma in order to achieve a quicker rehabilitation. However, one of the severe complications of cataract surgery is increased intraocular pressure due to the inflammatory response, the so-called reactive syndrome that occurs in the early postoperative period. Aim of the study was to evaluate the efficacy of a fixed